Eytan Stein

Eytan Stein at MSK led clinical development of IDH inhibitors in AML — the first cancer metabolic enzyme inhibitors to receive FDA approval. He led pivotal trials establishing enasidenib (IDH2 inhibitor) and ivosidenib (IDH1 inhibitor) activity in IDH-mutant relapsed/refractory AML, and has contributed to understanding differentiation syndrome and combination strategies in IDH-mutant AML, demonstrating the clinical potential of targeting cancer metabolic vulnerabilities.